David E. Lazar - 23 Mar 2026 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)

Reporting relationship: Director
Issuer ticker: INDP
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Mar 2026, 16:02:56 UTC
Prior SEC filing: 03 Mar 2026
Next SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for Indaptus Therapeutics, Inc. (INDP) on 24 Mar 2026.

Key facts

This page summarizes David E. Lazar's Form 4 filing for Indaptus Therapeutics, Inc. (INDP).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 24 Mar 2026, 16:02.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: Director
Address: 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 24 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDP transaction Derivative

Series AA Convertible Non-Redeemable Preferred Stock

Sale

Transaction value
Shares: -196,800
Change %: -66%
Price
Shares after: 103,200
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,936,000
Exercise price
Footnotes: F1, F2, F3

INDP transaction Derivative

Series AAA Convertible Non-Redeemable Preferred Stock

Sale

Transaction value
Shares: -700,000
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 105,000,000
Exercise price
Footnotes: F1, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock.

Footnote F2

The Series AA Preferred Stock is convertible at the option of the holder for no additional consideration.

Footnote F3

The Series AA Preferred Stock is perpetual and therefore has no expiration date.

Footnote F4

The Series AAA Preferred Stock is convertible at the option of the holder for no additional consideration.

Footnote F5

The Series AAA Preferred Stock is perpetual and therefore has no expiration date.